Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.

Related Articles Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. Inflamm Bowel Dis. 2017 Oct;23(10):1689-1701 Authors: Cross RK Abstract BACKGROUND: The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the safety and tolerability of topically acting corticosteroids and biologic therapies versus oral systemic corticosteroids for ulcerative colitis (UC). METHODS: The PubMed database…

Read More

Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.

Related Articles Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol. 2017 Aug 04;: Authors: Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, Watanabe M, Hibi T Abstract BACKGROUND: Budesonide foam is used for the topical treatment of distal ulcerative colitis. This phase III study was performed to confirm mucosal healing and other therapeutic effects of twice-daily budesonide 2-mg foam in patients with mild-to-moderate ulcerative colitis including…

Read More

CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis.

CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis. J Clin Gastroenterol. 2017 Jul 21;: Authors: Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, Martin ST, Buckley M, Sheridan J, Horgan G, Mulcahy HE, Cullen G, Doherty GA Abstract INTRODUCTION: Identifying hospitalized patients with acute severe ulcerative colitis (ASUC) who will be refractory to corticosteroid therapy and require rescue therapy remains difficult. Hypoalbuminemia worsens with time during hospitalization and is associated with rapid clearance of and reduced response to infliximab (IFX) rescue….

Read More

Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.

Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol. 2017 Jul 04;: Authors: Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve…

Read More

Exclusive enteral nutrition therapy in pediatric Crohn’s disease results in long-term avoidance of corticosteroids: results of a propensity-score matched cohort analysis.

Exclusive enteral nutrition therapy in pediatric Crohn’s disease results in long-term avoidance of corticosteroids: results of a propensity-score matched cohort analysis. J Crohns Colitis. 2017 May 27;: Authors: Connors J, Basseri S, Grant A, Giffin N, Mahdi G, Noble A, Rashid M, Otley A, Van Limbergen J Abstract Background & Aims: Exclusive enteral nutrition (EEN) is recommended as first-line induction therapy for pediatric Crohn’s disease (CD) although corticosteroids (CS) are still used commonly. Our aim was to compare short- and long-term disease outcomes of pediatric CD patients initially managed with…

Read More

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians’ practice.

Related Articles Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians’ practice. World J Gastroenterol. 2017 Apr 28;23(16):2995-3002 Authors: Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN Abstract AIM: To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates (5ASA) with corticosteroids (CS) versus corticosteroids alone for patients with active ulcerative…

Read More

Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011.

Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011. Inflamm Bowel Dis. 2017 Mar 31;: Authors: Narula N, Borges L, Steinhart AH, Colombel JF Abstract BACKGROUND/HYPOTHESIS: Before the availability of biological therapies, corticosteroids and narcotics were frequently used in patients with inflammatory bowel disease (IBD) because of a paucity of disease-modifying therapies. The increased accessibility to effective biologicals for IBD over the last decade should be leading to less use of corticosteroids and narcotic medications. This…

Read More

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial. J Crohns Colitis. 2017 Mar 04;: Authors: Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP Abstract Background and Aims.: Safety and efficacy of budesonide multimatrix, an oral extended-release second-generation corticosteroid designed for targeted delivery throughout the colon, was examined for induction of remission in patients with mild to moderate ulcerative colitis refractory to baseline mesalamine therapy. Methods.: A randomized, double-blind, placebo-controlled, multicenter trial…

Read More
<< Go Back